Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected milestones related to its gene therapy pipeline candidates for 2026. Beam ...
Beam stock launched to a 10-month high Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302. Beam TherapeuticsBEAM is testing its drug in ...
The Beam Foundation has disclosed plans for an upcoming venture fund in Abu Dhabi targeting blockchain gaming projects. According to a Dec. 11 announcement, the fund will launch in the first half of ...
Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...
Beam Suntory has seen its plans to build a £150m ($190m) Scotch whisky maturation site approved. The Laphroaig whisky owner applied for planning permission to build the 70,000 square metre warehouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results